Hodgkin's lymphoma epidemiology and demographics: Difference between revisions

	Hodgkin's lymphoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Hodgkin's lymphoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
Staging
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray Findings
CT
MRI
Ultrasound
Biopsy
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Hodgkin's lymphoma epidemiology and demographics On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Hodgkin's lymphoma epidemiology and demographics All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Hodgkin's lymphoma epidemiology and demographics
CDC on Hodgkin's lymphoma epidemiology and demographics
Hodgkin's lymphoma epidemiology and demographics in the news
Blogs on Hodgkin's lymphoma epidemiology and demographics
Directions to Hospitals Treating Hodgkin's lymphoma
Risk calculators and risk factors for Hodgkin's lymphoma epidemiology and demographics

← Older edit Newer edit →

VisualWikitext

Revision as of 15:29, 11 June 2014

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2]

Overview

Unlike some other lymphomas, whose incidence increases with age, Hodgkin's lymphoma has a bimodal incidence curve; that is, it occurs most frequently in two separate age groups, the first being young adulthood (age 15–35) and the second being in those over 55 years old although these peaks may vary slightly with nationality.^[1] Overall, it is more common in men, except for the nodular sclerosis variant (see below), which is more common in women.

The annual incidence of Hodgkin's lymphoma is about 1/25,000 people, and the disease accounts for slightly less than 1% of all cancers worldwide.

The incidence of Hodgkin's lymphoma is increased in patients with HIV infection.^[2] In contrast to many other lymphomas associated with HIV infection it occurs most commonly in patients with higher CD4 T cell counts.

Epidemiology and Demographics

Prevalence

In the United States, the age adjusted prevalence of Hodgkin's lymphoma is 0.035% in 2011.^[3]

Incidence

The delay-adjusted incidence of Hodgkin's lymphoma in 2011 was estimated to be 2.8 per 100,000 persons in the United States.^[3]

In 2011, the age-adjusted incidence of Hodgkin's lymphoma was 2.71 per 100,000 persons in the United States.^[3]

Age

While the overall age adjusted incidence of Hodgkin's lymphoma in the United States between 2007 and 2011 is 2.7 per 100,000, the age-adjusted incidence of Hodgkin's lymphoma by age category is:^[3]
- Between 20 and 29 years: 4.1-4,5 per 100,000
- Under 65 years: 2.5 per 100,000
- 65 and over: 4.2 per 100,000

Gender

In the United States, the age adjusted prevalence of Hodgkin's lymphoma by gender in 2011 is:^[3]
- In males: 0.0372%
- In females: 0.0331%

In the United States, the delay-adjusted incidence of Hodgkin's lymphoma by gender in 2011 is:^[3]
- In males: 3.22 per 100,000 persons
- In females: 2.42 per 100,000 persons

In the United States, the age-adjusted incidence of Hodgkin's lymphoma by gender on 2011 is:^[3]
- In males: 3.11 per 100,000 persons
- In females: 2.34 per 100,000 persons

Shown below is an image depicting the delay-adjusted incidence and observed incidence of invasive esophageal cancer by gender and race in the United States between YEAR and YEAR. These graphs are adapted from SEER: The Surveillance, Epidemiology, and End Results Program of the National Cancer Institute.^[3]

[Insert figure x.1 from the report]

Race

Shown below is a table depicting the age adjusted prevalence of Hodgkin's lymphoma by race in 2011 in the United States.^[3]

	All Races	White	Black	Asian/Pacific Islander	Hispanic
Age-adjusted prevalence	0.035%	0.04%	0.0321%	0.0126%	0.0236%

Shown below is an image depicting the incidence of Hodgkin's lymphoma by race in the United States between YEAR and YEAR.^[3]

[Insert figure x.2 from the report]

Percent Distribution of Hodgkin's lymphoma by Histology

Among patients with histologically confirmed cases of Hodgkin's lymphoma, the percent distribution of the types of the disease between YEAR and YEAR in the United States are:^[3]
- Type X: _____ %
- Type Y: _____ %
- Type Z: _____ %

References

↑ Mauch, Peter (1999). Hodgkin's Disease. Lippincott Williams & Wilkins. pp. 62–64. ISBN 0-7817-1502-4. Unknown parameter |coauthors= ignored (help)
↑ Biggar RJ, Jaffe ES, Goedert JJ, Chaturvedi A, Pfeiffer R, Engels EA (2006). "Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS". Blood. 108 (12): 3786–91. doi:10.1182/blood-2006-05-024109. PMID 16917006.
↑ ^3.00 ^3.01 ^3.02 ^3.03 ^3.04 ^3.05 ^3.06 ^3.07 ^3.08 ^3.09 ^3.10 Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.

Template:WikiDoc Sources

[1] Mauch, Peter (1999). Hodgkin's Disease. Lippincott Williams & Wilkins. pp. 62–64. ISBN 0-7817-1502-4. Unknown parameter |coauthors= ignored (help)

[2] Biggar RJ, Jaffe ES, Goedert JJ, Chaturvedi A, Pfeiffer R, Engels EA (2006). "Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS". Blood. 108 (12): 3786–91. doi:10.1182/blood-2006-05-024109. PMID 16917006.

[SEER-3] 3.00 ^3.01 ^3.02 ^3.03 ^3.04 ^3.05 ^3.06 ^3.07 ^3.08 ^3.09 ^3.10 Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.

[1]

[2]

[3]

@@ Line 13: / Line 13: @@
 ===Prevalence===
-* In the United States, the [age adjusted] prevalence of (insert disease name here) is _____ % in 2011.<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref>
+* In the United States, the age adjusted prevalence of Hodgkin's lymphoma is 0.035% in 2011.<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref>
 ===Incidence===
-* The delay-adjusted incidence of (insert disease name here) in 2011 was estimated to be _____ per 100,000 persons in the United States.<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref>
+* The delay-adjusted incidence of Hodgkin's lymphoma in 2011 was estimated to be 2.8 per 100,000 persons in the United States.<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref>
-* In 2011, the age-adjusted incidence of (insert disease name here) was _____ per 100,000 persons in the United States.<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref>
+* In 2011, the age-adjusted incidence of Hodgkin's lymphoma was 2.71 per 100,000 persons in the United States.<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref>
 ===Age===
-* While the overall age adjusted incidence of (insert disease name here) in the United States between YEAR and YEAR is _____ per 100,000, the age-adjusted incidence of (insert disease name here) by age category is:<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref>
+* While the overall age adjusted incidence of Hodgkin's lymphoma in the United States between 2007 and 2011 is 2.7 per 100,000, the age-adjusted incidence of Hodgkin's lymphoma by age category is:<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref>
-** Under 65 years: _____ per 100,000
+** Between 20 and 29 years: 4.1-4,5 per 100,000
-** 65 and over: _____ per 100,000
+** Under 65 years: 2.5 per 100,000
+** 65 and over: 4.2 per 100,000
 ===Gender===
-* In the United States, the [age adjusted] prevalence of (insert disease name here) by gender in 2011 is:<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref>
+* In the United States, the age adjusted prevalence of Hodgkin's lymphoma by gender in 2011 is:<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref>
-** In males: _____ %
+** In males: 0.0372%
-** In females: _____ %
+** In females: 0.0331%
-* In the United States, the delay-adjusted incidence of (insert disease name here) by gender in 2011 is:<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref>
+* In the United States, the delay-adjusted incidence of Hodgkin's lymphoma by gender in 2011 is:<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref>
-** In males: _____ per 100,000 persons
+** In males: 3.22 per 100,000 persons
-** In females: _____ per 100,000 persons
+** In females: 2.42 per 100,000 persons
-* In the United States, the age-adjusted incidence of (insert disease name here) by gender on 2011 is:<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref>
+* In the United States, the age-adjusted incidence of Hodgkin's lymphoma by gender on 2011 is:<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref>
-** In males: _____ per 100,000 persons
+** In males: 3.11 per 100,000 persons
-** In females: _____ per 100,000 persons
+** In females: 2.34 per 100,000 persons
 Shown below is an image depicting the delay-adjusted incidence and observed incidence of invasive esophageal cancer by gender and race in the United States between YEAR and YEAR.  These graphs are adapted from [[SEER]]: The Surveillance, Epidemiology, and End Results Program of the National Cancer Institute.<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref>
@@ Line 47: / Line 48: @@
 ===Race===
-* Shown below is a table depicting the [age adjusted] prevalence of (insert disease name here) by race in 2011 in the United States.<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref>
+* Shown below is a table depicting the age adjusted prevalence of Hodgkin's lymphoma by race in 2011 in the United States.<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref>
 {| style="cellpadding=0; cellspacing= 0; width: 600px;"
@@ Line 53: / Line 54: @@
 |style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align=center | || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align=center |'''All Races''' ||style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align=center |'''White''' || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align=center |'''Black''' || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align=center |'''Asian/Pacific Islander'''  || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align=center |'''Hispanic'''
 |-
-| style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align=center |'''Age-adjusted prevalence'''|| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |  ||style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |  ||style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |  ||style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |   ||style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |
+| style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align=center |'''Age-adjusted prevalence'''|| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |0.035% ||style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |0.04% ||style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |0.0321%||style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |0.0126% ||style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |0.0236%
 |}
-* In the United States, the race that is most susceptible to developing this disease/condition, is the ____ race.<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref>
+Shown below is an image depicting the incidence of Hodgkin's lymphoma by race in the United States between YEAR and YEAR.<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref>
-Shown below is an image depicting the incidence of (insert disease name here) by race in the United States between YEAR and YEAR.<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref>
 [Insert figure x.2 from the report]
-===Percent Distribution of (insert disease name here) by Histology===
+===Percent Distribution of Hodgkin's lymphoma by Histology===
-* Among patients with histologically confirmed cases of (insert disease name here), the percent distribution of the types of the disease between YEAR and YEAR in the United States are:<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref>
+* Among patients with histologically confirmed cases of Hodgkin's lymphoma, the percent distribution of the types of the disease between YEAR and YEAR in the United States are:<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref>
 **  Type X: _____ %
 ** Type Y: _____ %